Combination Olanzapine and Samidorphan for the Management of Schizophrenia and Bipolar 1 Disorder in Adults: A Narrative Review
Schizophrenia is a debilitating psychotic disorder characterized by positive symptoms such as delusions, hallucinations, and disorganized thoughts, and negative symptoms like lack of effect or motivation. Bipolar 1 disorder (B1D) is a psychiatric illness characterized by recurrent manic episodes in...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Medical Publishing
2022-04-01
|
| Series: | Health Psychology Research |
| Online Access: | https://doi.org/10.52965/001c.34224 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825139388800040960 |
|---|---|
| author | Hannah W. Haddad Elena Boardman Brooke Williams Rama Mouhaffel Adam M. Kaye Alan D. Kaye |
| author_facet | Hannah W. Haddad Elena Boardman Brooke Williams Rama Mouhaffel Adam M. Kaye Alan D. Kaye |
| author_sort | Hannah W. Haddad |
| collection | DOAJ |
| description | Schizophrenia is a debilitating psychotic disorder characterized by positive symptoms such as delusions, hallucinations, and disorganized thoughts, and negative symptoms like lack of effect or motivation. Bipolar 1 disorder (B1D) is a psychiatric illness characterized by recurrent manic episodes in alternation with depressive episodes and interspersed periods of euthymia, ultimately resulting in psychological distress and impairment of daily functioning. Effective treatments are needed for both schizophrenia and B1D to reach the treatment goals of reducing the debilitating symptomology, improving social functioning and quality of life, and increasing the chances of recovery and more favorable long-term outcomes. To date, olanzapine is one of the most efficacious atypical antipsychotics (AAPs) for the treatment of both schizophrenia and B1D and is associated with fewer extrapyramidal effects compared to other treatments. However, compared to other AAPs, olanzapine is associated with a greater chance of metabolic syndrome, limiting its clinical use and affecting treatment compliance. Samidorphan mitigates the weight gain side effects of olanzapine by antagonizing μ-, κ-, and δ-opioid receptors. The use of combination drugs to treat psychiatric conditions is an emerging field with the goal of increasing therapeutic efficacy and decreasing undesirable side effects. Clinical trials have demonstrated combination on olanzapine and samidorphan (OLZ/SAM) treatment resulted in significantly less weight gain than olanzapine monotherapy. Clinical trial patients reported improvements in symptoms of psychosis, reduced weight gain, and overall satisfaction with their treatment. OLZ/SAM has been as shown to be a safe and effective pharmaceutical option for the clinical management of schizophrenia and B1D. |
| format | Article |
| id | doaj-art-889b6fb17f92498da05a4dfa275efb46 |
| institution | Kabale University |
| issn | 2420-8124 |
| language | English |
| publishDate | 2022-04-01 |
| publisher | Open Medical Publishing |
| record_format | Article |
| series | Health Psychology Research |
| spelling | doaj-art-889b6fb17f92498da05a4dfa275efb462025-02-11T20:30:28ZengOpen Medical PublishingHealth Psychology Research2420-81242022-04-01102Combination Olanzapine and Samidorphan for the Management of Schizophrenia and Bipolar 1 Disorder in Adults: A Narrative ReviewHannah W. HaddadElena BoardmanBrooke WilliamsRama MouhaffelAdam M. KayeAlan D. KayeSchizophrenia is a debilitating psychotic disorder characterized by positive symptoms such as delusions, hallucinations, and disorganized thoughts, and negative symptoms like lack of effect or motivation. Bipolar 1 disorder (B1D) is a psychiatric illness characterized by recurrent manic episodes in alternation with depressive episodes and interspersed periods of euthymia, ultimately resulting in psychological distress and impairment of daily functioning. Effective treatments are needed for both schizophrenia and B1D to reach the treatment goals of reducing the debilitating symptomology, improving social functioning and quality of life, and increasing the chances of recovery and more favorable long-term outcomes. To date, olanzapine is one of the most efficacious atypical antipsychotics (AAPs) for the treatment of both schizophrenia and B1D and is associated with fewer extrapyramidal effects compared to other treatments. However, compared to other AAPs, olanzapine is associated with a greater chance of metabolic syndrome, limiting its clinical use and affecting treatment compliance. Samidorphan mitigates the weight gain side effects of olanzapine by antagonizing μ-, κ-, and δ-opioid receptors. The use of combination drugs to treat psychiatric conditions is an emerging field with the goal of increasing therapeutic efficacy and decreasing undesirable side effects. Clinical trials have demonstrated combination on olanzapine and samidorphan (OLZ/SAM) treatment resulted in significantly less weight gain than olanzapine monotherapy. Clinical trial patients reported improvements in symptoms of psychosis, reduced weight gain, and overall satisfaction with their treatment. OLZ/SAM has been as shown to be a safe and effective pharmaceutical option for the clinical management of schizophrenia and B1D.https://doi.org/10.52965/001c.34224 |
| spellingShingle | Hannah W. Haddad Elena Boardman Brooke Williams Rama Mouhaffel Adam M. Kaye Alan D. Kaye Combination Olanzapine and Samidorphan for the Management of Schizophrenia and Bipolar 1 Disorder in Adults: A Narrative Review Health Psychology Research |
| title | Combination Olanzapine and Samidorphan for the Management of Schizophrenia and Bipolar 1 Disorder in Adults: A Narrative Review |
| title_full | Combination Olanzapine and Samidorphan for the Management of Schizophrenia and Bipolar 1 Disorder in Adults: A Narrative Review |
| title_fullStr | Combination Olanzapine and Samidorphan for the Management of Schizophrenia and Bipolar 1 Disorder in Adults: A Narrative Review |
| title_full_unstemmed | Combination Olanzapine and Samidorphan for the Management of Schizophrenia and Bipolar 1 Disorder in Adults: A Narrative Review |
| title_short | Combination Olanzapine and Samidorphan for the Management of Schizophrenia and Bipolar 1 Disorder in Adults: A Narrative Review |
| title_sort | combination olanzapine and samidorphan for the management of schizophrenia and bipolar 1 disorder in adults a narrative review |
| url | https://doi.org/10.52965/001c.34224 |
| work_keys_str_mv | AT hannahwhaddad combinationolanzapineandsamidorphanforthemanagementofschizophreniaandbipolar1disorderinadultsanarrativereview AT elenaboardman combinationolanzapineandsamidorphanforthemanagementofschizophreniaandbipolar1disorderinadultsanarrativereview AT brookewilliams combinationolanzapineandsamidorphanforthemanagementofschizophreniaandbipolar1disorderinadultsanarrativereview AT ramamouhaffel combinationolanzapineandsamidorphanforthemanagementofschizophreniaandbipolar1disorderinadultsanarrativereview AT adammkaye combinationolanzapineandsamidorphanforthemanagementofschizophreniaandbipolar1disorderinadultsanarrativereview AT alandkaye combinationolanzapineandsamidorphanforthemanagementofschizophreniaandbipolar1disorderinadultsanarrativereview |